TLR7 and neoplasm: Notably, the PEG4‐maleimide modification reduces IMDQ's capacity to stimulate TLR7/8, which is in line with the effect of other IMDQ chemical modifications reported in our previous studies.[36, 44] However, this lowered IMDQ activity was compensated for by its direct targeting to the relevant cells, as demonstrated by the significant anti‐tumor effects of the anti‐MMR Nb‐IMDQ.